EGFR and lung carcinoma: Kolesar et al. explored the use of liquid biopsy in guiding the selection of TKI therapies at various stages of lung cancer treatment to enhance the precision and efficacy of therapy for lung cancer patients with EGFR variants and resistance to standard treatments [140].